Annual SG&A
$51.95 M
+$26.84 M+106.85%
31 December 2023
Summary:
CymaBay Therapeutics annual selling, general & administrative expenses is currently $51.95 million, with the most recent change of +$26.84 million (+106.85%) on 31 December 2023. During the last 3 years, it has risen by +$35.23 million (+210.72%).CBAY Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$19.81 M
+$7.56 M+61.75%
31 December 2023
Summary:
CymaBay Therapeutics quarterly selling, general & administrative expenses is currently $19.81 million, with the most recent change of +$7.56 million (+61.75%) on 31 December 2023. Over the past year, it has increased by +$7.56 million (+61.75%).CBAY Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$3.72 B
-$105.37 M-2.92%
31 December 2023
Summary:
CymaBay Therapeutics TTM selling, general & administrative expenses is currently -$3.72 billion, with the most recent change of -$105.37 million (-2.92%) on 31 December 2023. Over the past year, it has dropped by -$3.76 billion (-9539.58%).CBAY TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CBAY Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +106.8% | +61.8% | -9539.6% |
| 3 y3 years | +210.7% | +282.4% | -10000.0% |
| 5 y5 years | +261.3% | +338.8% | -10000.0% |
CBAY Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | at high | at high | -7257.7% |
CymaBay Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $51.95 M(+106.9%) | $19.81 M(+61.7%) | $51.95 M(+31.9%) |
| Sept 2023 | - | $12.24 M(+5.8%) | $39.39 M(+19.2%) |
| June 2023 | - | $11.58 M(+39.1%) | $33.05 M(+20.8%) |
| Mar 2023 | - | $8.32 M(+14.9%) | $27.35 M(+8.9%) |
| Dec 2022 | $25.12 M(+9.0%) | $7.25 M(+22.7%) | $25.12 M(+4.8%) |
| Sept 2022 | - | $5.90 M(+0.4%) | $23.97 M(+3.1%) |
| June 2022 | - | $5.88 M(-3.4%) | $23.25 M(-2.7%) |
| Mar 2022 | - | $6.09 M(-0.3%) | $23.89 M(+3.7%) |
| Dec 2021 | $23.04 M(+37.8%) | $6.10 M(+17.9%) | $23.04 M(+4.2%) |
| Sept 2021 | - | $5.18 M(-20.6%) | $22.12 M(+6.1%) |
| June 2021 | - | $6.52 M(+24.5%) | $20.85 M(+18.9%) |
| Mar 2021 | - | $5.24 M(+1.0%) | $17.54 M(+4.9%) |
| Dec 2020 | $16.72 M(-13.1%) | $5.18 M(+32.7%) | $16.72 M(+4.1%) |
| Sept 2020 | - | $3.91 M(+21.7%) | $16.07 M(-3.6%) |
| June 2020 | - | $3.21 M(-27.3%) | $16.67 M(-7.3%) |
| Mar 2020 | - | $4.42 M(-2.5%) | $17.99 M(-6.5%) |
| Dec 2019 | $19.24 M(+33.8%) | $4.53 M(+0.4%) | $19.24 M(+2.0%) |
| Sept 2019 | - | $4.51 M(-0.3%) | $18.86 M(+7.0%) |
| June 2019 | - | $4.53 M(-20.0%) | $17.63 M(+5.7%) |
| Mar 2019 | - | $5.66 M(+36.2%) | $16.67 M(+15.9%) |
| Dec 2018 | $14.38 M | $4.16 M(+26.9%) | $14.38 M(+9.6%) |
| Sept 2018 | - | $3.28 M(-8.3%) | $13.12 M(+8.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | $3.57 M(+6.0%) | $12.05 M(-0.1%) |
| Mar 2018 | - | $3.37 M(+16.6%) | $12.06 M(-2.6%) |
| Dec 2017 | $12.39 M(+28.4%) | $2.89 M(+31.0%) | $12.39 M(+0.4%) |
| Sept 2017 | - | $2.21 M(-38.3%) | $12.33 M(+0.7%) |
| June 2017 | - | $3.58 M(-3.2%) | $12.25 M(+12.6%) |
| Mar 2017 | - | $3.70 M(+30.4%) | $10.88 M(+12.9%) |
| Dec 2016 | $9.64 M(+8.7%) | $2.84 M(+33.3%) | $9.64 M(+12.1%) |
| Sept 2016 | - | $2.13 M(-3.8%) | $8.60 M(-0.8%) |
| June 2016 | - | $2.21 M(-10.0%) | $8.67 M(-0.8%) |
| Mar 2016 | - | $2.46 M(+37.0%) | $8.74 M(-1.4%) |
| Dec 2015 | $8.87 M(+8.4%) | $1.80 M(-18.4%) | $8.87 M(-5.7%) |
| Sept 2015 | - | $2.20 M(-3.7%) | $9.41 M(+5.8%) |
| June 2015 | - | $2.29 M(-11.7%) | $8.89 M(+7.5%) |
| Mar 2015 | - | $2.59 M(+11.0%) | $8.27 M(+1.1%) |
| Dec 2014 | $8.19 M(+68.0%) | $2.33 M(+38.2%) | $8.19 M(+3.0%) |
| Sept 2014 | - | $1.69 M(+1.3%) | $7.94 M(+14.5%) |
| June 2014 | - | $1.67 M(-33.4%) | $6.94 M(+7.7%) |
| Mar 2014 | - | $2.50 M(+19.6%) | $6.45 M(+32.3%) |
| Dec 2013 | $4.87 M(+15.8%) | $2.09 M(+206.1%) | $4.87 M(+75.2%) |
| Sept 2013 | - | $683.00 K(-41.7%) | $2.78 M(+32.6%) |
| June 2013 | - | $1.17 M(+26.7%) | $2.10 M(+126.7%) |
| Mar 2013 | - | $925.00 K | $925.00 K |
| Dec 2012 | $4.21 M | - | - |
FAQ
- What is CymaBay Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for CymaBay Therapeutics?
- What is CymaBay Therapeutics annual SG&A year-on-year change?
- What is CymaBay Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for CymaBay Therapeutics?
- What is CymaBay Therapeutics quarterly SG&A year-on-year change?
- What is CymaBay Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for CymaBay Therapeutics?
- What is CymaBay Therapeutics TTM SG&A year-on-year change?
What is CymaBay Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of CBAY is $51.95 M
What is the all time high annual SG&A for CymaBay Therapeutics?
CymaBay Therapeutics all-time high annual selling, general & administrative expenses is $51.95 M
What is CymaBay Therapeutics annual SG&A year-on-year change?
Over the past year, CBAY annual selling, general & administrative expenses has changed by +$26.84 M (+106.85%)
What is CymaBay Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of CBAY is $19.81 M
What is the all time high quarterly SG&A for CymaBay Therapeutics?
CymaBay Therapeutics all-time high quarterly selling, general & administrative expenses is $19.81 M
What is CymaBay Therapeutics quarterly SG&A year-on-year change?
Over the past year, CBAY quarterly selling, general & administrative expenses has changed by +$7.56 M (+61.75%)
What is CymaBay Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of CBAY is -$3.72 B
What is the all time high TTM SG&A for CymaBay Therapeutics?
CymaBay Therapeutics all-time high TTM selling, general & administrative expenses is $51.95 M
What is CymaBay Therapeutics TTM SG&A year-on-year change?
Over the past year, CBAY TTM selling, general & administrative expenses has changed by -$3.76 B (-9539.58%)